Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study

Abstract Background While the number of therapeutic options for treating inflammatory bowel diseases (IBD) is increasing, evidence for rational treatment decisions is scarce in many cases. In particular, appropriate biomarkers to predict the response to the anti-α4β7 integrin antibody vedolizumab ar...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Clarissa Allner, Michaela Melde, Emily Becker, Friederike Fuchs, Laura Mühl, Entcho Klenske, Lisa Müller, Nadine Morgenstern, Konstantin Fietkau, Simon Hirschmann, Raja Atreya, Imke Atreya, Markus F. Neurath, Sebastian Zundler
Format: Artigo
Idioma:Inglês
Publicat: BMC 2020-04-01
Col·lecció:BMC Gastroenterology
Matèries:
Inflammatory bowel diseases
T cells
Vedolizumab
Adhesion
Gut homing
Accés en línia:http://link.springer.com/article/10.1186/s12876-020-01253-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars